Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRTR20250213019
- Term of Validity
- 13 February 2025 - 13 February 2026
- Company's Country
- Turkey
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- Turkish Biotech SME is looking for spanish partners for submitting a proposal for Türkiye and Spain call for R&D projects
- Full Description
-
This project aims to develop a 3D bioprinted tumor model using patient-derived cells and ECM-based bioinks to enhance cancer drug screening, tumor progression studies, and immunotherapy research. Key objectives include:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses. - Advantages and Innovations
- Traditional 2D cell cultures and animal models fail to accurately replicate the complex tumor microenvironment, leading to low translatability of preclinical drug testing results. Extracellular Matrix (ECM)-supported 3D bioprinting offers a more physiologically relevant alternative, allowing for the recreation of the tumor microenvironment, cellular interactions, and drug resistance mechanisms in a laboratory setting.
- Technical Specification or Expertise Sought
-
The company is looking for spanish profit organisations who can take part as a project partner for 1-2 of following tasks:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses. - Stage of Development
- Concept stage
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
Partner Sought
- Expected Role of a Partner
-
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses. - Type and Size of Partner
- SME <=10
- SME 50 - 249
- SME 11-49
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Eureka
- Call title and identifier
-
Türkiye and Spain call for R&D projects
- Coordinator required
-
No
- Deadline for EoI
- Deadline of the call
- Eureka
Dissemination
- Market keywords
- 05007007 - Other medical/health related (not elsewhere classified)
- Targeted countries
- All countries